Ultra High-Volume Scanners

PRODUCTS

  • The QTRAP 4500 System offers reliable quantitation and library searching - with 100X more full-scan sensitivity over basic triple quads in the same class.

  • Although each micro-manufacturing cell is considered autonomous, MTD must also depend on proper quality assurance techniques, which come in the form of micro metrology and testing.

  • INCREASED PRODUCTION RATE AND BETTER YIELDS=EFFICIENCY
    The NP-155 pharmaceutical tablet press is equipped with essential features that were designed and engineered to produce quality tablets at an affordable price. With its double-sided design, the NP-155 pharmaceutical tablet press produces two tablets per press turret cycle, allowing you to double your tablet production while running at standard single-sided rotary press speeds. The NP-155 provides significant versatility for delivering exceptional tablet quality, consistency, and production.

  • LMD 6 Laser Microdissection Microscope

    Dissection Perfection

    Laser Microdissection (LMD, also known as Laser Capture Microdissection or LCM) enables users to isolate specific single cells or entire areas of tissue. Powered by a unique laser design and dynamic software, Leica LMD systems allow users to easily isolate Regions of Interest (ROI) from entire areas of tissue down to single cells or even subcellular structures such as chromosomes.

    LMD is typically used in genomics (DNA), transcriptomics (mRNA, miRNA), proteomics, metabolomics, and even next generation sequencing (NGS). Researchers in neurology, cancer research, plant analysis, forensics or climate research rely on this method. Furthermore, LMD is a perfect tool for live cell culture (LCC), for cloning and re-cultivation, manipulation or downstream analysis.

    We move the laser, not the sample. And we use gravity for collection. That is why our LMD systems provide you with perfectly cut, contamination-free, analysis-ready dissectates.

  • There are clearly defined pathways for drug approval, and choosing the right regulatory pathway for your drug development program requires a thorough understanding of sections 505(b)(1) and 505(b)(2) of the Federal Food, Drug, and Cosmetics (FD&C) Act.

WHITE PAPERS AND CASE STUDIES

NEWS